VivoSeq
Other

Mhspc

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

mHSPC is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
Active, not recruiting·JJena University Hospital·Phase 3·NCT05676203·250 enrolled
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Recruiting·UUNICANCER·Phase 3·NCT06496581·500 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)